Literature DB >> 26415750

Evaluation of a dilution method for non-evaluable results in the detection of Chlamydia trachomatis and Neisseria gonorrhoeae with the Cobas 4800 platform.

Manuel Parra-Sánchez1, Silvia García-Rey2, Ismail Zakariya-Yousef Breval2, Celestina Sierra-Atienza2, Samuel Bernal-Martínez2, José Carlos Palomares-Folía2.   

Abstract

INTRODUCTION: A variable percentage of samples analysed using the Cobas 4800 assay can give an invalid result by PCR inhibition or erroneous due to incorrect DNA extraction with the Cobas 4800 CT/NG test.
METHOD: An analysis was performed using the vortex agitation and dilution protocol on the original sample (swab or urine) for a total of 116 samples. In order to analyse the sensitivity of this method, 100 samples (swabs and urine) with known results were retested.
RESULTS: A total of 98.3% (114/116) of the samples analysed were resolved with this protocol with 100% agreement after reviewing clinical data, Gram stain, and other samples analysed in parallel from the same patient. DISCUSSION: The data indicate no loss of sensitivity with this protocol; thus Cobas 4800 users could use this method without the need for alternative methods.
Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Chlamydia trachomatis; Inhibición; Inhibition; Neisseria gonorrhoeae; Polymerase Chain Reaction; Reacción en cadena de la polimerasa

Mesh:

Substances:

Year:  2015        PMID: 26415750     DOI: 10.1016/j.eimc.2015.06.017

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  1 in total

1.  Factors associated with repeat rectal Neisseria gonorrhoeae and Chlamydia trachomatis screening following inconclusive nucleic acid amplification testing: A potential missed opportunity for screening.

Authors:  Cheríe S Blair; Omai B Garner; Bettina Pedone; Sam Elias; W Scott Comulada; Raphael J Landovitz
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.